

Psilocybin selectively suppresses REM sleep in the Wistar Kyoto rat model of treatmentresistant depression

Sandor Kantor, Lauren Giggins, Neil Upton and Mark Duxon

> Transpharmation Ltd. London, United Kingdom

> > www.transpharmation.co.uk Copyright © 2021 Transpharmation. All Rights Reserved.



The Wistar-Kyoto (WKY) rat model of treatment resistant depression





WKY rats have abnormally increased REM sleep that is suppressed by ketamine but not by SSRIs



www.transpharmation.co.uk Copyright © 2021 Transpharmation. All Rights Reserved.

Δ

Time in REM

REM latency

C Time in BE



Sleep-wake behavior was recorded in SD and WKY rats after vehicle and psilocybin treatment



Test Article	Dose level	Dose Volume,	N
		Route	
Vehicle*	N.A.	3 ml/kg, i.p.	8 SD / 8 WKY
Psilocybin	1 mg/kg	3 ml/kg, i.p.	8 SD / 8 WKY
Psilocybin	3 mg/kg	3 ml/kg, i.p.	8 SD / 8 WKY
Psilocybin	10 mg/kg	3 ml/kg, i.p.	8 SD / 8 WKY
*Saline			



NR - NREM sleep, R - REM sleep, W - wakefulness



Psilocybin suppressed REM sleep in SD rats without affecting wakefulness or NREM sleep



*p < 0.05 vs Vehicle treatment (Dunnett post-test)

www.transpharmation.co.uk Copyright © 2021 Transpharmation. All Rights Reserved.

Psilocybin effectively and selectively suppressed REM sleep in WKY rats



*p < 0.05 vs Vehicle treatment (Dunnett post-test)

Transpharmation

Science that translates into resul



Psilocybin suppressed EEG gamma oscillations during wakefulness in SD rats



*p < 0.05 vs Vehicle treatment (Dunnett post-test)

www.transpharmation.co.uk Copyright © 2021 Transpharmation. All Rights Reserved.



Conclusions

- Suppression of REM sleep by antidepressants is one of the most consistent findings in patients with depression.
- Therefore, the decreased amount of REM sleep after psilocybin treatment could indicate antidepressant-like properties of the drug in WKY rats.
- Changes in REM sleep in WKY rats may serve as a key translational tool in an effort to discover novel therapeutics against TRD.



Thank you



Sandor Kantor PhD Scientific Lead



Lauren Giggins Senior Scientist





Neil Upton PhD Founder & Chief Scientific Officer



Mark Duxon PhD Chief Executive Officer